Table 4.
Phase Ill clinical studies assessing first-line combined immunotherapy for HCC (in progress)
| Study | Experimental group | Control group | Population | |
|---|---|---|---|---|
| NCT03764293 | Camrelizumab combined with apatinib | Sorafenib | Global | |
|
|
||||
| NCT03713593 | Pembrolizumab combined with lenvatinib | Placebo combined with lenvatinib | Global | |
|
|
||||
| NCT04523493 | Toripalimab combined with lenvatinib | Placebo combined with lenvatinib | Global | |
|
|
||||
| NCT04723004 | Toripalimab combined with bevacizumab | Sorafenib | China | |
|
|
||||
| NCT04194775 | CS1003 (PD-1 monoclonal antibody) combined with lenvatinib | Placebo combined with lenvatinib | Global | |
|
|
||||
| NCT03605706 | Camrelizumab combined with FOLFOX4 chemotherapy | Placebo combined with FOLFOX4 chemotherapy | China | |